2023年6月13日

舊金山,加利福尼亞,美國舊金山,6月13日2023(全球通訊社)——SmithRx,下一代藥房福利管理(PBM)公司今天宣布,它將提供YUSIMRY,抗生物仿製,其成員90%以上不到抗價格列表。與馬克古巴成本加製藥公司合作,中國人民銀行,SmithRx將涵蓋YUSIMRY當它在2023年7月初推出。YUSIMRY將可以通過網上郵購藥店為569.27美元成本加藥物+分配和運輸費用,而抗的當前價格每箱6922美元。獨特的這種合作,SmithRx成員將能夠運用他們的保險金YUSIMRY付現成本進一步降低。“與傳統pbm SmithRx重視透明度和前期成本節約。抗通常是雇主的藥物費用所以提供一個低成本的替代將產生重大影響,”傑克Frenz說SmithRx的創始人和CEO。“我們興奮與成本加藥物把這個生物仿製我們的成員——和他們的雇主和顯著降低成本。“抗,世界上最暢銷的藥物,也是美國最昂貴的藥物,用於治療各種自身免疫性疾病包括類風濕性關節炎、克羅恩病、潰瘍性結腸炎、和斑塊性銀屑病。使用抗超過300000病人在美國,biosimilar versions of it have only just come to market. This will be the first time that a Humira biosimilar is available to patients through a PBM at low and transparent price. When a previous biosimilar was released earlier this year, legacy PBMs made it available only through the standard model of high list prices coupled with opaque rebates. “We started SmithRx because the PBM model was broken,” said Frenz. “Our technology platform combined with our innovative sourcing channels allow us to find the lowest prices and pass through the savings to plan sponsors and patients.” "Working with SmithRx, a transparent PBM, has been a great experience for Mark Cuban Cost Plus Drug Company,” said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company. “Their commitment to transparency and efficiency aligns perfectly with our mission to provide affordable and accessible medications to all. Together, we are forging a new path in the pharmaceutical industry, ensuring that patients receive the best care at the most reasonable costs." On June 1, 2023, Mark Cuban Cost Plus Drug Company and Coherus Biosciences announced plans to offer Cost Plus Drug Company customers YUSIMRY (adalimumab-aqvh), a biosimilar of HUMIRA (adalimumab injection), in July 2023. SmithRx works with more than 250 broker offices and serves more than 2,500 employers coast to coast. After doubling managed members for the fifth consecutive year, SmithRx closed a $20 million Series B round led by Venrock in March 2022. About SmithRx Pharmacy costs have been rising rapidly over the past decade, putting strain on patients and employers throughout the country. SmithRx, a privately-held technology company was founded in 2016 with the goal of reducing these costs by operating with a 100 percent transparent, pass-through PBM business model. With this approach, SmithRx is forging new pathways to affordable drugs while giving clients full access to their data. SmithRx’s simple per member per month (PMPM) revenue model contrasts with legacy PBMs’ use of spread pricing and is fully aligned with its clients’ affordability goals. Learn more at https://smithrx.com/ About Mark Cuban Cost Plus Drug Company The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) aims to fundamentally change the way the pharmaceutical industry operates. As a public-benefit corporation, its social mission of improving public health is just as important as the bottom line. Cost Plus Drugs transparently charges a standard markup on every drug it sells. The costplusdrugs.com online pharmacy launched in January 2022 now carries over 1,000 prescription products, delivered by mail to thousands of happy customers every day. Cost Plus Drugs is working with health plans, managed-care organizations, pharmacy benefits managers (PBMs) and self-insured employers to bring these same savings to employer-sponsored benefit plans nationwide. Contact: